In first half of 2025, nov­el drug ap­provals are in line with pre­vi­ous years

Thou­sands of FDA staff de­par­tures since April have sparked con­cerns with­in the phar­ma in­dus­try that nov­el drug ap­proval dead­lines might slip.

But in the first …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER